Anxiety News and Research

Latest Anxiety News and Research

Ford and MIT explore automotive technology solutions to reduce driver stress

As Americans fight through the most stressful time of the year, Ford Motor Company and the Massachusetts Institute of Technology (MIT) are embarking on a plan to study driver workload and identify new opportunities to use in-vehicle technologies to improve driver safety by lowering stress.

31 Dec 2009

Overview of grief

A death of a loved one, a job loss, the end of a marriage, an illness or disability. Everyone faces losses and grief, but the toll that grief can take on the mind and body can catch many people by surprise.

30 Dec 2009

CORE, a biopsychosocial treatment center for weight loss

Earlier this month, leaders in the treatment of weight related disorders and psychiatry joined forces under the Comprehensive Obesity Recovery Effort (CORE, LLC).

30 Dec 2009

First animal model for studying schizophrenia

Scientists have created what appears to be a schizophrenic mouse by reducing the inhibition of brain cells involved in complex reasoning and decisions about appropriate social behavior.

29 Dec 2009

CAMFT encourages people to focus on emotional health in 2010

While most New Year's resolutions revolve around changing your outward appearance by losing weight or hitting the gym, the California Association of Marriage and Family Therapists (CAMFT) encourages people to rethink their New Year's resolutions this year to focus inward on their emotional health in 2010.

29 Dec 2009

Test tube experiments show slight changes in protein chemistry can eliminate Huntington's disease in mice

In Huntington's disease, a mutated protein in the body becomes toxic to brain cells. Recent studies have demonstrated that a small region adjacent to the mutated segment plays a major role in the toxicity. Two new studies supported by the National Institutes of Health show that very slight changes to this region can eliminate signs of Huntington's disease in mice.

28 Dec 2009

PHT comments on FDA's PRO Final Guidance

PHT Corporation, the leading provider of ePRO (electronic patient reported outcome) solutions used in more than 400 clinical trials worldwide, commented on the FDA’s recent release of a final guidance almost four years following a Draft Guidance on the topic. The Final Guidance is entitled: Guidance for Industry, Patient-Reported Outcomes Measures: Use in Medical Product Development to Support Labeling Claims.

24 Dec 2009

FDA issues Pfizer a Complete Response letter for Lyrica GAD monotherapy treatment

Pfizer Inc. announced today that the Food and Drug Administration (FDA) issued a Complete Response letter regarding the company’s New Drug Application (NDA) for Lyrica® (pregabalin) capsules CV as a monotherapy treatment for generalized anxiety disorder (GAD). The FDA determined that the data contained in the NDA were insufficient to support approval.

24 Dec 2009

New energy receptor theory of brain function

Dr. Mitchell Earl Gibson, best-selling author, board-certified physician, and CEO of Tybro Publications, has proposed a new energy receptor theory of brain function that might explain the efficacy of mantras and prayer in human illness.

24 Dec 2009

GI Dynamics' EndoBarrier non-surgical type 2 diabetes therapy receives European CE mark approval

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier™, a non-surgical therapy to treat type 2 diabetes and obesity. The CE marking (an acronym for the French "Conformite Europeenne") certifies that a product has met EU requirements for marketing in Europe. Clinical trials involving more than 270 patients have demonstrated the significant weight loss and diabetes improvement achieved with the EndoBarrier Gastrointestinal Liner.

22 Dec 2009

School intervention programs may promote psychological well-being among adolescents

A new study which has been conducted at the University of Bologna shows that brief psychological interventions in school may increase well-being among adolescents and these results persist after 6 months

22 Dec 2009

Women eligible for breast cancer screening with MRI decline to undergo the procedure, study shows

In a new study published in the January issue of Radiology, 42 percent of women eligible for breast cancer screening with MRI declined to undergo the procedure.

22 Dec 2009

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Neurocrine Biosciences, Inc. today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.

21 Dec 2009

CIGNA suggests the 'To Do' list to stay healthy during this holiday season

‘Tis the season for celebrating with family and friends -- and searching for those perfect gifts. CIGNA suggests adding another item to the top of the holiday “To Do” list: Be sure to take needed medications to stay healthy this holiday season and into the New Year.

19 Dec 2009

Study provides new definition on dyslexia

Contrary to popular belief, some very smart, accomplished people cannot read well. This unexpected difficulty in reading in relation to intelligence, education and professional status is called dyslexia, and researchers at Yale School of Medicine and University of California Davis, have presented new data that explain how otherwise bright and intelligent people struggle to read.

18 Dec 2009

A program to reduce depression and isolation among the elderly during holiday season

MyWay Village, the first senior-focused technology company to help seniors get online in an easy and social way by combining access to simplified technology with personal training and support, today announced that their Connected Living program is reducing depression and feelings of isolation especially during the holiday season within senior communities where the company's programs are being offered.

18 Dec 2009

Cannabis can cause depression and anxiety in teenagers

Canadian teenagers are among the largest consumers of cannabis worldwide. The damaging effects of this illicit drug on young brains are worse than originally thought, according to new research by Dr. Gabriella Gobbi, a psychiatric researcher from the Research Institute of the McGill University Health Centre. The new study, published in Neurobiology of Disease, suggests that daily consumption of cannabis in teens can cause depression and anxiety, and have an irreversible long-term effect on the brain.

18 Dec 2009

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today stated that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

18 Dec 2009

Neurocrine Biosciences to sell 4,784,689 shares of common stock to Venrock affiliates

Neurocrine Biosciences, Inc. today reported that it has entered into a privately negotiated transaction to sell an aggregate of 4,784,689 primary shares of its common stock to affiliates of Venrock at a price of $2.09 per share, raising aggregate gross proceeds to Neurocrine of approximately $10 million. Neurocrine expects the financing to close on or about December 22, 2009, subject to customary closing conditions.

17 Dec 2009

ASA offers practical ways for sufferers to take active role in treatment of pain

Whether the result of injury, illness or a chronic condition, 70 million Americans experience pain annually. The individual pain sufferer may experience a diminished quality of life, lack of mobility and added stress.

17 Dec 2009

Anxiety News and Research

Latest Anxiety News and Research

Ford and MIT explore automotive technology solutions to reduce driver stress

Overview of grief

CORE, a biopsychosocial treatment center for weight loss

First animal model for studying schizophrenia

CAMFT encourages people to focus on emotional health in 2010

Test tube experiments show slight changes in protein chemistry can eliminate Huntington's disease in mice

PHT comments on FDA's PRO Final Guidance

FDA issues Pfizer a Complete Response letter for Lyrica GAD monotherapy treatment

New energy receptor theory of brain function

GI Dynamics' EndoBarrier non-surgical type 2 diabetes therapy receives European CE mark approval

School intervention programs may promote psychological well-being among adolescents

Women eligible for breast cancer screening with MRI decline to undergo the procedure, study shows

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

CIGNA suggests the 'To Do' list to stay healthy during this holiday season

Study provides new definition on dyslexia

A program to reduce depression and isolation among the elderly during holiday season

Cannabis can cause depression and anxiety in teenagers

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Neurocrine Biosciences to sell 4,784,689 shares of common stock to Venrock affiliates

ASA offers practical ways for sufferers to take active role in treatment of pain

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Anxiety News and Research

Latest Anxiety News and Research

Industry Focus: Cell & Gene Therapy eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in